Related references
Note: Only part of the references are listed.First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Paul Baas et al.
LANCET (2021)
Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
Luca Cantini et al.
FRONTIERS IN ONCOLOGY (2020)
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
Michele Carbone et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes
Astero Klampatsa et al.
ONCOIMMUNOLOGY (2019)
Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
Rachel Grosser et al.
CANCER CELL (2019)
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers
Mark Yarchoan et al.
JCI INSIGHT (2019)
Driving CARs on the uneven road of antigen heterogeneity in solid tumors
Nan Chen et al.
CURRENT OPINION IN IMMUNOLOGY (2018)
Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1)
Samuel G. Armato et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies
Stefan Kiesgen et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Chimeric Antigen Receptor Therapy
Carl H. June et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation
Anne S. Tsao et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
18F-Fluorodeoxyglucose PET/CT and dynamic contrast-enhanced MRI as imaging biomarkers in malignant pleural mesothelioma
David O. Hall et al.
NUCLEAR MEDICINE COMMUNICATIONS (2018)
Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1
Takashi Eguchi et al.
ONCOTARGET (2017)
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors
Aurore Morello et al.
CANCER DISCOVERY (2016)
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Leonid Cherkassky et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
Gerard Zalcman et al.
LANCET (2016)
Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors
Mark M. Awad et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Chimeric antigen receptor T-cell therapy for solid tumors
Kheng Newick et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
Clinical manufacturing of CAR T cells: foundation of a promising therapy
Xiuyan Wang et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis
Anish Thomas et al.
ONCOTARGET (2015)
The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers
Hideki Ujiie et al.
ONCOIMMUNOLOGY (2015)
Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy
Ira Pastan et al.
CANCER RESEARCH (2014)
Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma
Stefan S. Kachala et al.
CLINICAL CANCER RESEARCH (2014)
Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-Like Phenotype, Distant Metastases and Decreased Survival
Gary Tozbikian et al.
PLOS ONE (2014)
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
Prasad S. Adusumilli et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Tissue and Serum Mesothelin Are Potential Markers of Neoplastic Progression in Barrett's Associated Esophageal Adenocarcinoma
Nabil P. Rizk et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2012)
Mesothelin Overexpression Promotes Mesothelioma Cell Invasion and MMP-9 Secretion in an Orthotopic Mouse Model and in Epithelioid Pleural Mesothelioma Patients
Elliot L. Servais et al.
CLINICAL CANCER RESEARCH (2012)
Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma
Adam J. Bograd et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Antonio Di Stasi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy
Daniel Hollyman et al.
JOURNAL OF IMMUNOTHERAPY (2009)
A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity
Yang Feng et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center
Raja M. Flores et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
NJ Vogelzang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR zeta/CD28 receptor
J Maher et al.
NATURE BIOTECHNOLOGY (2002)
Share Paper
